Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Blaskovich
Mark Arnold Thomas Blaskovich, Queensland AU
| Patent application number | Description | Published |
|---|---|---|
| 20090221557 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS - The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases. | 09-03-2009 |
| 20090221558 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR - The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases. | 09-03-2009 |
Mark Arnold Thomas Blaskovich, Bardon AU
| Patent application number | Description | Published |
|---|---|---|
| 20090131374 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases. | 05-21-2009 |
Phillip Blaskovich, Salem, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110091549 | Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels - Methods and compositions relate to modulating the release profile of drug molecules from a hydrogel by controlling the kinetics of the pH transition of the hydrogel. The hydrogel is formed by in situ polymerization and includes a drug molecule having a pKa between the pH of the formed hydrogel and the physiologic environment in which the hydrogel is placed. | 04-21-2011 |
| 20110092899 | Prevention Of Premature Gelling Of Delivery Devices For pH Dependent Forming Materials - The present disclosure provides treatment of an apparatus, in embodiments a delivery device, which prevents premature gelling of any materials or precursor(s) of a pH dependent forming material, in embodiments a hydrogel, dispensed by the delivery device. The pH microenvironment near the surface of a lumen of the device, in embodiments the tip of a spray applicator through which the material to be dispensed is expelled from the device, may be controlled to prevent premature gelling. | 04-21-2011 |
| 20110093057 | Mitigating Thrombus Formation On Medical Devices By Influencing pH Microenvironment Near The Surface - The present disclosure provides treatments of medical devices which inhibit thrombus formation. At least a portion of a substrate of a medical device includes a surface possessing a functionality and/or surface charge adapted to modulate the pH of the surface of the medical device, as well as the pH microenvironment near the surface of a medical device. | 04-21-2011 |